Special Issue

Kidney Cancer—New Insights into Diagnosis and Treatment

Message from the Guest Editor

In 2020, 431,288 new cases and 179,368 deaths from kidney cancer were recorded worldwide, which places this disease at the forefront of cancers. Over the past two decades, great efforts have been made to improve diagnosis and treatment outcomes. Molecular biomarkers have been investigated and introduced into clinical practice, and new pathological and clinical classifications have been proposed to account for tumor behavior and risk of disease recurrence. At the same time, new surgical and pharmacological approaches have been developed to improve treatment outcomes. Nevertheless, many aspects remain a matter of debate regarding accurate diagnosis, targeted therapy, and multidisciplinary management.

This Special Issue of Cancers will cover all aspects of kidney cancer, including original research into advanced imaging, molecular characterization, current and experimental treatment options, and quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Guest Editor

Dr. Bartosz Małkiewicz

University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland

Deadline for manuscript submissions

closed (31 July 2022)

Uro

___

an Open Access Journal by MDPI

Uro

an Open Access Journal
by MDPI

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Tommaso Cai
Department of Urology, Santa Chiara Regional and Teaching Hospital,
38123 Trento, Italy

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid
by authors or their institutions.

Rapid Publication:
manuscripts are peer-reviewed and a first decision is
provided to authors approximately 39.4 days after
submission; acceptance to publication is undertaken in 7.7
days (median values for papers published in this journal in
the first half of 2025).

Recognition of Reviewers:
APC discount vouchers, optional signed peer review, and
reviewer names published annually in the journal.